Open Access

miR‑9 depletion suppresses the proliferation of osteosarcoma cells by targeting p16

  • Authors:
    • Song Gao
    • Jianchao Wang
    • Shujian Tian
    • Jianping Luo
  • View Affiliations

  • Published online on: April 12, 2019     https://doi.org/10.3892/ijo.2019.4783
  • Pages: 1921-1932
  • Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteosarcoma (OS) is a common primary malignancy in adolescents and children. MicroRNAs (miRNAs or miRs) can regulate the progression of OS. Herein, we explored the target genes and effects of miR‑9 in OS. Cell growth, colony formation and cell cycle were respectively examined using a cell counting kit‑8 (CCK‑8), crystal violet staining and flow cytometry. The target gene of miR‑9 was predicted according to the MicroRNA.org website. Luciferase activity was examined using a dual luciferase reporter gene assay kit. The corresponding factors levels were analyzed by carrying out reverse transcription‑quantitative PCR (RT‑qPCR) and western blot analysis. A mouse model of OS was also established and the volume and weight of the tumors of the mice with OS were measured. The levels of p16 in the mice with OS were detected by immunohistochemistry (IHC). The data revealed a high expression of miR‑9 and a low expression of p16 in the OS tissue. p16 was found to be the target gene for miR‑9 in OS. miR‑9 depletion decreased the proliferation and colony formation of Saos‑2 cells by arresting the cells at the G1 phase, accompanied by the downregulation of cyclin A, cyclin D1 and c‑Myc expression levels. Moreover, miR‑9 depletion inhibited the phosphorylation of p38, c‑Jun N‑terminal kinase (JNK) and extracellular signal‑regulated kinase (ERK). In vivo, miR‑9 depletion decreased the tumor volume and weight and increased p16 expression in the mouse tumor tissues. Nevertheless, p16 silencing reversed the suppressive effects of miR‑9 inhibitors on OS cells. On the whole, the findings of this study substantiate that miR‑9 depletion suppresses cell proliferation by targeting p16 in OS and by mediating the activation of the ERK/p38/JNK pathway.

References

1 

Garcia-Moure M, Martinez-Vélez N, Patiño-García A and Alonso MM: Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope. J Bone Oncol. 9:41–47. 2016. View Article : Google Scholar

2 

Misaghi A, Goldin A, Awad M and Kulidjian AA: Osteosarcoma: A comprehensive review. SICOT J. 4:122018. View Article : Google Scholar : PubMed/NCBI

3 

Guenther LM, Rowe RG, Acharya PT, Swenson DW, Meyer SC, Clinton CM, Guo D, Sridharan M, London WB, Grier HE, et al: Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. Pediatr Blood Cancer. 65:652018. View Article : Google Scholar

4 

Huang Z and Lou C: Application of the alteration uptake ratio of 99mTc-MIBI scintigraphy for evaluating the efficacy of neoadjuvant chemotherapy in osteosarcoma patients. Hell J Nucl Med. 21:55–59. 2018.PubMed/NCBI

5 

Cavit A, Özcanli H, Sançmiş M, Ocak GA and Gürer EI: Tumorous conditions of the hand: A retrospective review of 402 cases. Turk Patoloji Derg. 34:66–72. 2018.

6 

Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI

7 

Lee J, Park H, Eom J and Kang SG: MicroRNA-mediated regulation of the development and functions of follicular helper T cells. Immune Netw. 18:e72018. View Article : Google Scholar : PubMed/NCBI

8 

Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI

9 

Wightman B, Ha I and Ruvkun G: Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation iC elegans. Cell. 75:855–862. 1993. View Article : Google Scholar : PubMed/NCBI

10 

Chen Z, Han Y, Song C, Wei H, Chen Y, Huang K, Li S, Ma D, Wang S, Wang J, et al: Systematic review and meta-analysis of the prognostic significance of microRNAs in cervical cancer. Oncotarget. 9:17141–17148. 2017.

11 

Hershkovitz-Rokah O, Geva P, Salmon-Divon M, Shpilberg O and Liberman-Aronov S: Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas. Oncotarget. 9:7928–7941. 2018. View Article : Google Scholar : PubMed/NCBI

12 

Ichii O and Horino T: MicroRNAs associated with the development of kidney diseases in humans and animals. J Toxicol Pathol. 31:23–34. 2018. View Article : Google Scholar : PubMed/NCBI

13 

Iguchi T, Sakurai K, Tamai S and Mori K: Circulating liver-specific microRNAs in cynomolgus monkeys. J Toxicol Pathol. 31:3–13. 2018. View Article : Google Scholar : PubMed/NCBI

14 

Wang H, Peng R, Wang J, Qin Z and Xue L: Circulating microRNAs as potential cancer biomarkers: The advantage and disadvantage. Clin Epigenetics. 10:592018. View Article : Google Scholar : PubMed/NCBI

15 

Chen M, Liu YY, Zheng MQ, Wang XL, Gao XH, Chen L and Zhang GM: microRNA-544 promoted human osteosarcoma cell proliferation by downregulating AXIN2 expression. Oncol Lett. 15:7076–7082. 2018.PubMed/NCBI

16 

Ding J, Sha L, Shen P, Huang M, Cai Q and Li J: MicroRNA-18a inhibits cell growth and induces apoptosis in osteosarcoma by targeting MED27. Int J Oncol. 53:329–338. 2018.PubMed/NCBI

17 

Tang W, Wang W, Zhao Y and Zhao Z: MicroRNA-874 inhibits cell proliferation and invasion by targeting cyclin-dependent kinase 9 in osteosarcoma. Oncol Lett. 15:7649–7654. 2018.PubMed/NCBI

18 

Fenger JM, Roberts RD, Iwenofu OH, Bear MD, Zhang X, Couto JI, Modiano JF, Kisseberth WC and London CA: MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines. BMC Cancer. 16:7842016. View Article : Google Scholar : PubMed/NCBI

19 

Jang MH, Kim HJ, Gwak JM, Chung YR and Park SY: Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer. Hum Pathol. 68:69–78. 2017. View Article : Google Scholar : PubMed/NCBI

20 

Snezhkina AV, Krasnov GS, Zhikrivetskaya SO, Karpova IY, Fedorova MS, Nyushko KM, Belyakov MM, Gnuchev NV, Sidorov DV, Alekseev BY, et al: Overexpression of microRNAs miR-9, -98, and -199 correlates with the downregulation of HK2 expression in colorectal cancer. Mol Biol (Mosk). 52:220–230. 2018.In Russian. View Article : Google Scholar

21 

Wang H, Wu Q, Zhang Y, Zhang HN, Wang YB and Wang W: TGF-β1-induced epithelial-mesenchymal transition in lung cancer cells involves upregulation of miR-9 and downregulation of its target, E-cadherin. Cell Mol Biol Lett. 22:222017. View Article : Google Scholar

22 

Zheng L, Qi T, Yang D, Qi M, Li D, Xiang X, Huang K and Tong Q: microRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting cyclin D1 and Ets1. PLoS One. 8:e557192013. View Article : Google Scholar : PubMed/NCBI

23 

She H, He Y, Zhao Y and Mao Z: Autophagy in inflammation: The p38α MAPK-ULK1 axis. Macrophage (Houst). 5:e16292018.

24 

Tang Q, Tong M, Zheng G, Shen L, Shang P and Liu H: Masquelet’s induced membrane promotes the osteogenic differentiation of bone marrow mesenchymal stem cells by activating the Smad and MAPK pathways. Am J Transl Res. 10:1211–1219. 2018.

25 

Li S, Ma YM, Zheng PS and Zhang P: GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2. J Exp Clin Cancer Res. 37:802018. View Article : Google Scholar : PubMed/NCBI

26 

Pinal N, Martín M, Medina I and Morata G: Short-term activation of the Jun N-terminal kinase pathway in apoptosis-deficient cells of Drosophila induces tumorigenesis. Nat Commun. 9:15412018. View Article : Google Scholar : PubMed/NCBI

27 

Yang S, Guo L, Su Y, Wen J, Du J, Li X, Liu Y, Feng J, Xie Y, Bai Y, et al: Nitric oxide balances osteoblast and adipocyte lineage differentiation via the JNK/MAPK signaling pathway in periodontal ligament stem cells. Stem Cell Res Ther. 9:1182018. View Article : Google Scholar : PubMed/NCBI

28 

Aroui S, Aouey B, Chtourou Y, Meunier AC, Fetoui H and Kenani A: Naringin suppresses cell metastasis and the expression of matrix metalloproteinases (MMP-2 and MMP-9) via the inhibition of ERK-P38-JNK signaling pathway in human glioblastoma. Chem Biol Interact. 244:195–203. 2016. View Article : Google Scholar : PubMed/NCBI

29 

Speth Z, Islam T, Banerjee K and Resat H: EGFR signaling pathways are wired differently in normal 184A1L5 human mammary epithelial and MDA-MB-231 breast cancer cells. J Cell Commun Signal. 11:341–356. 2017. View Article : Google Scholar : PubMed/NCBI

30 

Chen HJ, Lin CM, Lee CY, Shih NC, Peng SF, Tsuzuki M, Amagaya S, Huang WW and Yang JS: Kaempferol suppresses cell metastasis via inhibition of the ERK-p38-JNK and AP-1 signaling pathways in U-2 OS human osteosarcoma cells. Oncol Rep. 30:925–932. 2013. View Article : Google Scholar : PubMed/NCBI

31 

Joo SS and Yoo YM: Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: Therapeutic implications for prostate cancer. J Pineal Res. 47:8–14. 2009. View Article : Google Scholar : PubMed/NCBI

32 

Zhao Li T, Ge J, Yang J, Song J, Wang X, Mao C, Zhang J, Zou Y, Liu YY, et al: Particulate matter facilitates C6 glioma cells activation and the release of inflammatory factors through MAPK and JAK2/STAT3 pathways. Neurochem Res. 41:1969–1981. 2016. View Article : Google Scholar : PubMed/NCBI

33 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar

34 

Faustino-Rocha A, Oliveira PA, Pinho-Oliveira J, Teixeira-Guedes C, Soares-Maia R, da Costa RG, Colaço B, Pires MJ, Colaço J, Ferreira R, et al: Estimation of rat mammary tumor volume using caliper and ultrasonography measurements. Lab Anim (NY). 42:217–224. 2013. View Article : Google Scholar

35 

Drakaki A, Hatziapostolou M, Polytarchou C, Vorvis C, Poultsides GA, Souglakos J, Georgoulias V and Iliopoulos D: Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway. BMC Cancer. 15:5422015. View Article : Google Scholar : PubMed/NCBI

36 

Xu T, Liu X, Han L, Shen H, Liu L and Shu Y: Up-regulation of miR-9 expression as a poor prognostic biomarker in patients with non-small cell lung cancer. Clin Transl Oncol. 16:469–475. 2014. View Article : Google Scholar

37 

Zhu SW, Li JP, Ma XL, Ma JX, Yang Y, Chen Y and Liu W: miR-9 modulates osteosarcoma cell growth by targeting the GCIP tumor suppressor. Asian Pac J Cancer Prev. 16:4509–4513. 2015. View Article : Google Scholar : PubMed/NCBI

38 

Laios A, O’Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, et al: Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 7:352008. View Article : Google Scholar : PubMed/NCBI

39 

Xu Lu J, Liu X, Peng X, Zhang Y, Wang B, Luo L, Peng H, Li X, Tian GW, et al: Predictive value of miR-9 as a potential biomarker for nasopharyngeal carcinoma metastasis. Br J Cancer. 110:392–398. 2014. View Article : Google Scholar :

40 

Jia GQ, Zhang MM, Wang K, Zhao GP, Pang MH and Chen ZY: Long non-coding RNA PlncRNA-1 promotes cell proliferation and hepatic metastasis in colorectal cancer. J Cell Biochem. 119:7091–7104. 2018. View Article : Google Scholar : PubMed/NCBI

41 

Zhou Q, You C, Zheng C, Gu Y, Gu H, Zhang R, Wu H and Sun B: 3-Nitroacridine derivatives arrest cell cycle at G0/G1 phase and induce apoptosis in human breast cancer cells may act as DNA-target anticancer agents. Life Sci. 206:1–9. 2018. View Article : Google Scholar : PubMed/NCBI

42 

Liu W, Liu C, Yin B and Peng XZ: Functions of miR-9 and miR-9* during aging in SAMP8 mice and their possible mechanisms. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 37:253–258. 2015.PubMed/NCBI

43 

Di Sante G, Di Rocco A, Pupo C, Casimiro MC and Pestell RG: Hormone-induced DNA damage response and repair mediated by cyclin D1 in breast and prostate cancer. Oncotarget. 8:81803–81812. 2017. View Article : Google Scholar : PubMed/NCBI

44 

Li Y, Zhang J, Gao W, Zhang L, Pan Y, Zhang S and Wang Y: Insights on structural characteristics and ligand binding mechanisms of CDK2. Int J Mol Sci. 16:9314–9340. 2015. View Article : Google Scholar : PubMed/NCBI

45 

Roskoski R Jr: Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacol Res. 107:249–275. 2016. View Article : Google Scholar : PubMed/NCBI

46 

Goetzman ES and Prochownik EV: The role for Myc in coordinating glycolysis, oxidative phosphorylation, glutaminolysis, and fatty acid metabolism in normal and neoplastic tissues. Front Endocrinol (Lausanne). 9:1292018. View Article : Google Scholar

47 

Wang H, Zhang W, Zuo Y, Ding M, Ke C, Yan R, Zhan H, Liu J and Wang J: miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer. Tumour Biol. 36:9631–9640. 2015. View Article : Google Scholar : PubMed/NCBI

48 

Zhou ZX, Zhang ZP, Tao ZZ and Tan TZ: MiR-632 promotes laryngeal carcinoma cell proliferation, migration and invasion through negative regulation of GSK3β. Oncol Res: Mar. 21:2018Epub ahead of print. View Article : Google Scholar

49 

Lee JK, Lee KH, Kim SA, Kweon SS, Cho SH, Shim HJ, Bae WK, Chung IJ, Chung WK, Yoon TM, et al: p16 as a prognostic factor for the response to induction chemotherapy in advanced hypo-pharyngeal squamous cell carcinoma. Oncol Lett. 15:6571–6577. 2018.PubMed/NCBI

50 

Ottria L, Candotto V, Cura F, Baggi L, Arcuri C, Nardone M, Gaudio RM, Gatto R, Spadari F and Carinci F: HPV acting on E-cadherin, p53 and p16: Literature review. J Biol Regul Homeost Agents. 32(Suppl 1): 73–79. 2018.PubMed/NCBI

51 

Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 368:753–756. 1994. View Article : Google Scholar : PubMed/NCBI

52 

Hirama T and Koeffler HP: Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood. 86:841–854. 1995.PubMed/NCBI

53 

Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:704–707. 1993. View Article : Google Scholar : PubMed/NCBI

54 

Zhu Pu X, Fu L, Fan Y, Zheng Z, Zhang J, Yang B, Guan J, Wu W, Ye HQ, et al: Companied P16 genetic and protein status together providing useful information on the clinical outcome of urinary bladder cancer. Medicine (Baltimore). 97:e03532018. View Article : Google Scholar :

55 

Goody D and Pfeifer A: MicroRNAs in brown and beige fat. Biochim Biophys Acta Mol Cell Biol Lipids. 1864:29–36. 2018. View Article : Google Scholar : PubMed/NCBI

56 

Guo J and Cheng Y: MicroRNA-1247 inhibits lipopolysac-charides-induced acute pneumonia in A549 cells via targeting CC chemokine ligand 16. Biomed Pharmacother. 104:60–68. 2018. View Article : Google Scholar : PubMed/NCBI

57 

Song Z, Cooper DKC, Cai Z and Mou L: Expression and Regulation profile of mature MicroRNA in the pig: Relevance to xenotransplantation. BioMed Res Int. 2018:29839082018. View Article : Google Scholar : PubMed/NCBI

58 

O’Loghlen A, Brookes S, Martin N, Rapisarda V, Peters G and Gil J: CBX7 and miR-9 are part of an autoregulatory loop controlling p16(INK) (4a). Aging Cell. 14:1113–1121. 2015. View Article : Google Scholar

59 

Wang C, Zhang X, Zhang C, Zhai F, Li Y and Huang Z: MicroRNA-155 targets MAP3K10 and regulates osteosarcoma cell growth. Pathol Res Pract. 213:389–393. 2017. View Article : Google Scholar : PubMed/NCBI

60 

Gui ZL, Wu TL, Zhao GC, Lin ZX and Xu HG: MicroRNA-497 suppress osteosarcoma by targeting MAPK/Erk pathway. Bratisl Lek Listy. 118:449–452. 2017.PubMed/NCBI

61 

Zhang J, Cheng J, Zeng Z, Wang Y, Li X, Xie Q, Jia J, Yan Y, Guo Z, Gao J, et al: Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma. Oncotarget. 6:42040–42052. 2015. View Article : Google Scholar : PubMed/NCBI

62 

Ben-Hamo R and Efroni S: Correction: Gene expression and network-based analysis reveals a novel role for hsa-miR-9 and drug control over the p38 network in glioblastoma multiforme progression. Genome Med. 4:872012. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 54 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Gao, S., Wang, J., Tian, S., & Luo, J. (2019). miR‑9 depletion suppresses the proliferation of osteosarcoma cells by targeting p16. International Journal of Oncology, 54, 1921-1932. https://doi.org/10.3892/ijo.2019.4783
MLA
Gao, S., Wang, J., Tian, S., Luo, J."miR‑9 depletion suppresses the proliferation of osteosarcoma cells by targeting p16". International Journal of Oncology 54.6 (2019): 1921-1932.
Chicago
Gao, S., Wang, J., Tian, S., Luo, J."miR‑9 depletion suppresses the proliferation of osteosarcoma cells by targeting p16". International Journal of Oncology 54, no. 6 (2019): 1921-1932. https://doi.org/10.3892/ijo.2019.4783